학술논문
Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study
Document Type
article
Author
Tatyana N. Sokolova; Tatyana I. Solov'eva; Svetlana N. Aleksakhina; Grigorii A. Janus; Alla Goryainova; Mark I. Gluzman; Rashida V. Orlova; Anastasiya I. Stukan; Ruslan A. Zukov; Alena V. Zyuzyukina; Yulia N. Murunova; Aleksandr V. Sultanbaev; Elena N. Vorobeva; Leonid M. Mikhaevich; Victoria N. Pyliv; Anna N. Lysenko; Zarema K. Khachmamuk; Andrey E. Kozlov; Sergey Y. Bakharev; Shahen G. Parsyan; Elena I. Rossokha; Leri D. Osidze; Irina S. Shumskaya; Anna V. Agaeva; Tatiana A. Kasmynina; Veronika V. Klimenko; Kamila T. Akhmetgareeva; Almira A. Vakhitova; Madina D. Chakhkieva; Vadim N. Dmitriev; Yana I. Bakshun; Alexey E. Vasilyev; Dunya D. Gasimly; Nadezhda A. Kravchenko; Dmitriy A. Maksimov; Alfia I. Nesterova; Ineza O. Sharvashidze; Christina H. Gadzaova; Galina G. Rakhmankulova; Zaur M. Khamgokov; Irina K. Amirkhanova; Ludmila V. Bembeeva; Vladimir I. Vladimirov; Oleg L. Petrenko; Natalia G. Ruskova; Ekaterina L. Serikova; Ksenia S. Subbotina; Svetlana A. Tkachenko; Victor L. Chang; Sanal P. Erdniev; Victoria S. Barbara; Anna V. Vasilevskaya; Yulia V. Mikheeva; Nataliya O. Popova; Ekaterina P. Startseva; Anastasia V. Fateeva; Denis Y. Yukalchuk; Anna A. Grechkina; Khedi S. Musaeva; Svetlana V. Odintsova; Alena S. Stel'makh; Petimat I. Khabibulaeva; Alina G. Khlobystina; Kseniya A. Shvaiko; Elena A. Basova; Irina A. Bogomolova; Marina B. Bolieva; Viktor E. Goldberg; Marianna V. Kibisheva; Konstantin V. Menshikov; Dmitrii V. Ryazanov; Mariya L. Stepanova; Yana A. Udalova; Aleksandr V. Shkradyuk; Yana S. Chapko; Anna A. Shchukina; Idris M. Khabriev; Dmitrii V. Kirtbaya; Alexey M. Degtyarev; Aleksandr A. Epkhiev; Yana A. Tyugina; Mirza A. Murachuev; Aleksandr V. Togo; Aglaya G. Ievleva; Evgenii N. Imyanitov
Source
Современная онкология, Vol 24, Iss 1, Pp 12-23 (2022)
Subject
Language
Russian
ISSN
1815-1434
1815-1442
1815-1442
Abstract
Background. By 2020, breast cancer (BC) has become the most frequent malignancy in the world. The most common type of BC is HR+/HER2-negative cancer,2540% of which harbors PIK3CA mutations that affect the catalytic subunit of the PI3K protein. PIK3CA alterations are actionable, as such neoplasms can be treated with a combination of fulvestrant and the PI3K inhibitor alpelisib. As PIK3CA mutations have an extremely versatile effect on the characteristics of a tumor cell, numerous associations of PIK3CA mutations and various clinico-pathological characteristics of BC can be traced. Aim. Our aim was to clarify the information on the frequency and spectrum of PIK3CA mutations in Russian patients with HR+/HER2- advanced BC, and to study the association of PIK3CA mutations with clinical and pathological parameters of BC. Materials and methods. Tissue samples from 694 patients with HR+/HER2- advanced BC (mixed population of primary metastatic and relapsed tumors) who received any line of anti-cancer treatment in Dec 2020 to June 2021 in Russian Federation were analyzed by high-resolution melting, allele-specific PCR, digital droplet PCR and Sanger sequencing (exons 7,9, and 20 of the PIK3CA gene). Mutation rates in different BC subgroups were compared using the Fishers exact test. The age at diagnosis in patients with different PIK3CA status was compared using the MannWhitney U-test. The relationship between the PIK3CA status and the degree of tumor differentiation was compared using the CochraneArmitage test for trends. Luminal A and B BC expression subtypes were distinguished with surrogate IHC markers according to St.-Gallen recommendations (2013). Results. Mutations were identified in 220/694 (32%) BC patients. The three most frequent missense substitutions in the PIK3CA gene (p.E542K, p.E545K, and p.H1047R) accounted for 190/220 (86%) mutations. Associations of PIK3CA mutations with luminal A subtype of BC, low proliferation index, small size of the primary tumor, and absence of signs of hereditary cancer were revealed. Associations of mutations in the kinase domain of PIK3CA (p.H1047R) with late recurrence of locally advanced BC and with non-Slavic ethnic origin of patients were found. Conclusion. PIK3CA mutation rate of 32% confirms high prevalence of mutation in Russian population, with some differences reflecting the ethnic origin of patients.